
    
      PRIMARY OBJECTIVE:

      I. To collect preliminary statistical data (mean changes and standard deviations) on two
      omega-3 supplementation (omega-3 fatty acid) regimens (1.65 g/day and 3.3 g/day) compared to
      placebo for reducing cancer-related fatigue (CRF) in fatigued breast cancer survivors.

      OUTLINE: Patients are randomized to 1 of 3 arms.

      ARM I: Patients receive low-dose omega-3 fatty acid supplementation orally (PO) twice daily
      (BID) and placebo PO BID for 6 weeks.

      ARM II: Patients receive high-dose omega-3 fatty acid supplementation PO BID for 6 weeks.

      ARM III: Patients receive placebo PO BID for 6 weeks.
    
  